Gilead Sciences, Inc. (GILD) stock
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 12/30102% above fair value
$168.98−1.28 (-0.75%)
Close on Nov 18, 2026Market cap $209.59BP/E –Yield 1.87%
Gilead Sciences free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Gilead Sciences's free cash flow for the twelve months ending Sep 30, 2026 was $13.78B, up 50.4% year over year. For fiscal 2025 it was $9.46B, down 8.2% from the year before. Over ten years it grew -7.4% a year on average. The highest annual figure on record is $20.50B in fiscal 2015.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.46B | -8.2% |
| FY2024 | Dec 31, 2024 | $10.31B | +38.9% |
| FY2023 | Dec 31, 2023 | $7.42B | -11.1% |
| FY2022 | Dec 31, 2022 | $8.34B | -22.8% |
| FY2021 | Dec 31, 2021 | $10.81B | +43.7% |
| FY2020 | Dec 31, 2020 | $7.52B | -9.6% |
| FY2019 | Dec 31, 2019 | $8.32B | +11.3% |
| FY2018 | Dec 31, 2018 | $7.48B | -33.9% |
| FY2017 | Dec 31, 2017 | $11.31B | -30.6% |
| FY2016 | Dec 31, 2016 | $16.30B | -20.5% |
| FY2015 | Dec 31, 2015 | $20.50B | +67.2% |
| FY2014 | Dec 31, 2014 | $12.26B | +320.6% |
| FY2013 | Dec 31, 2013 | $2.92B | +4.2% |
| FY2012 | Dec 31, 2012 | $2.80B | -20.2% |
| FY2011 | Dec 31, 2011 | $3.51B | +26.5% |
| FY2010 | Dec 31, 2010 | $2.77B | -2.7% |
| FY2009 | Dec 31, 2009 | $2.85B | +40.5% |
| FY2008 | Dec 31, 2008 | $2.03B | +27.5% |
| FY2007 | Dec 31, 2007 | $1.59B | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $4.80B | +21.1% |
| Q2 FY2026 | Jun 30, 2026 | $3.43B | +376.8% |
| Q1 FY2026 | Mar 31, 2026 | $2.43B | +46.8% |
| Q4 FY2025 | Dec 31, 2025 | $3.12B | +10.4% |
| Q3 FY2025 | Sep 30, 2025 | $3.96B | -5.0% |
| Q2 FY2025 | Jun 30, 2025 | $720.00M | -39.7% |
| Q1 FY2025 | Mar 31, 2025 | $1.65B | -21.8% |
| Q4 FY2024 | Dec 31, 2024 | $2.83B | +44.7% |
| Q3 FY2024 | Sep 30, 2024 | $4.17B | +155.2% |
| Q2 FY2024 | Jun 30, 2024 | $1.20B | -45.7% |
| Q1 FY2024 | Mar 31, 2024 | $2.11B | +29.3% |
| Q4 FY2023 | Dec 31, 2023 | $1.95B | -18.1% |
| Q3 FY2023 | Sep 30, 2023 | $1.63B | -39.7% |
| Q2 FY2023 | Jun 30, 2023 | $2.20B | +32.5% |
| Q1 FY2023 | Mar 31, 2023 | $1.64B | +2.6% |
| Q4 FY2022 | Dec 31, 2022 | $2.39B | -21.7% |
| Q3 FY2022 | Sep 30, 2022 | $2.71B | -13.1% |
| Q2 FY2022 | Jun 30, 2022 | $1.66B | -24.5% |
| Q1 FY2022 | Mar 31, 2022 | $1.59B | -34.8% |
| Q4 FY2021 | Dec 31, 2021 | $3.05B | +75.7% |
| Q3 FY2021 | Sep 30, 2021 | $3.11B | +48.6% |
| Q2 FY2021 | Jun 30, 2021 | $2.20B | -9.3% |
| Q1 FY2021 | Mar 31, 2021 | $2.45B | +93.3% |
| Q4 FY2020 | Dec 31, 2020 | $1.74B | -27.0% |
| Q3 FY2020 | Sep 30, 2020 | $2.10B | -14.3% |
| Q2 FY2020 | Jun 30, 2020 | $2.42B | +12.3% |
| Q1 FY2020 | Mar 31, 2020 | $1.27B | -5.6% |
| Q4 FY2019 | Dec 31, 2019 | $2.38B | +13.4% |
| Q3 FY2019 | Sep 30, 2019 | $2.45B | +19.6% |
| Q2 FY2019 | Jun 30, 2019 | $2.16B | +69.0% |
| Q1 FY2019 | Mar 31, 2019 | $1.34B | -34.9% |
| Q4 FY2018 | Dec 31, 2018 | $2.10B | -17.2% |
| Q3 FY2018 | Sep 30, 2018 | $2.05B | -20.3% |
| Q2 FY2018 | Jun 30, 2018 | $1.28B | -62.5% |
| Q1 FY2018 | Mar 31, 2018 | $2.06B | -26.7% |
| Q4 FY2017 | Dec 31, 2017 | $2.53B | -24.8% |
| Q3 FY2017 | Sep 30, 2017 | $2.57B | – |
| Q2 FY2017 | Jun 30, 2017 | $3.40B | – |
| Q1 FY2017 | Mar 31, 2017 | $2.81B | – |
| Q4 FY2016 | Dec 31, 2016 | $3.37B | – |
See a number that looks wrong?